Cereno Scientific

The abstract titled “CS585 is a novel and highly selective IP receptor agonist for prevention of thrombosis”, was authored by Michael Holinstat, Sylviane Lambert, Pooja Yalavarthi, Livia Stanger, Adriana Yamaguchi and Andrew Rickenberg at University of Michigan, Ann Arbor, MI, US; Björn Dahlöf and Niklas Bergh, University of Gothenburg. The abstract has been selected to be presented as a moderated poster presentation by Dr. Michael Holinstat.

Details on the oral presentation at the ISTH 2023 Congress:

Presentation Title: CS585 is a novel and highly selective IP receptor agonist for prevention of thrombosis

Authors: Michael Holinstat, Sylviane Lambert, Pooja Yalavarthi, Livia Stanger, Adriana Yamaguchi and Andrew Rickenberg University of Michigan, Ann Arbor, MI, USA; Björn Dahlöf and Niklas Bergh University of Gothenburg, Gothenburg, Sweden.

Presentation Number: OC 61.3

Session Title: Manipulating Platelet Function

Presentation Date: Tuesday, June 27, 2023.

Presentation Time: 15:15 - 15:30 ET

Session Location: Room 710A

For further information, please contact:

Jonas Fogelberg, Interim CFO
Email: info@cerenoscientific.com
http://www.cerenoscientific.com/

About Cereno Scientific AB

Cereno Scientific is a clinical-stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH). CS1 is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties, all relevant for PAH. A clinical Phase II study is ongoing to evaluate CS1’s safety, tolerability, and efficacy in patients with PAH. A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Cereno also has two promising preclinical drug candidates in development for cardiovascular disease through research collaborations with the University of Michigan. Drug candidate CS014 is a novel HDAC inhibitor with epigenetic effects, selected for prevention of thrombosis as target indication. In preclinical studies it has been documented to regulate platelet activity, fibrinolysis and clot stability for prevention of thrombosis without increased risk of bleeding. Thrombosis prevention in venous or arterial and cardiovascular disease has been selected as the first indication area for CS014. Drug candidate CS585 is a prostacyclin receptor agonist that has been documented in preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Nasdaq First North (CRNO B). More information on www.cerenoscientific.com.